News Releases
NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, Canada, April 21, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced its
NervGen Provides Quarterly “At-The-Market” Equity Program Update
Vancouver, British Columbia, April 9, 2025 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing
NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates
Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for lead drug candidate, NVG-291, in
NervGen Initiates Expanded Access Policy
The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol for NVG-291 may proceed This news release constitutes a
NervGen Pharma to Host Virtual Investor Event
Key opinion leaders and company management will discuss the current spinal cord injury treatment landscape and NervGen’s Phase 1b/2a clinical trial evaluating NVG-291 in individuals
NervGen Pharma Grants Stock Options
Vancouver, Canada. March 14, 2025 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that
NervGen Pharma to Present at the Virtual Life Science Investor Forum
Vancouver, Canada, March 5, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that
NervGen Pharma Grants Stock Options
Vancouver, Canada. February 18, 2025 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that
NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
VANCOUVER, Canada, February 6, 2025 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that
NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Vancouver, Canada, January 29, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that
NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Topline data from the chronic cohort is expected in Q2 2025 Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for
NervGen Announces “At-The-Market” Equity Program
Vancouver, Canada, December 20, 2024 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative
NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates
Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completion NVG-300
NervGen Pharma to Present at the Stifel 2024 Healthcare Conference
Vancouver, Canada, November 7, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announced today that
NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Target enrollment in the chronic cohort close to completion Vancouver, Canada, September 30, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage